Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 94

Sort by

Sort Order Select

Journal Articles

Experience of Generic Imatinib As a First Line Therapy for Patients with Chronic Myeloid Leukemia in a Single Reference Institution

Gabriel Carvalho Pereira, MD, Fernanda B da Silva, BSc and MSc, Luisa Espirito Santo Oliveira, Pedro Marques Garibaldi, MD, Lorena Lobo Figueiredo-Pontes, MD PhD, Belinda Pinto Simões, MD PhD, Leonardo Carvalho Palma, MD PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 5916.

https://doi.org/10.1182/blood-2019-132045

Published: 2019

Journal Articles

Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study

Blood (2015) 126 (23): 133.

https://doi.org/10.1182/blood.V126.23.133.133

Published: 2015

Journal Articles

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Alexander M. Labeit, MDPhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Leanne M. Cork, BSc (Hons), Corinne A. Hedgley, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Wendy L. Osborne, MBBS (Hons) MRCP FRCPath, Gemma Gills, MSc BSc (Hons), Jane F. Apperley, MD, Tessa L. Holyoake, MDPhD, Ruth V. Bescoby, MSc BSc, Christopher Pocock, Thomas Zwingers, MSc, Philippa Burnell, Jenny L. Byrne, PhD, John H. McCullough, John M. Goldman, DM FRCP FRCPath, Richard E. Clark, MD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath

Blood (2015) 126 (23): 4024.

https://doi.org/10.1182/blood.V126.23.4024.4024

Published: 2015

Journal Articles

Impact of Proteomic Profile of Peripheral Blood and Bone Marrow Sera on Molecular Response in Patients with Chronic Myeloid Leukemia: Preliminary Data

Nicola Sgherza, Vito Garrisi, Giacoma De Tullio, MSc, Simona Serratì, Angela Iacobazzi, Antonello Rana, Angela La Pietra, Giacomo Loseto, Vito Cafagna, Vincenza de Fazio, Carla Minoia, Rosa Angarano, Ines Abbate, Attilio Guarini

Blood (2014) 124 (21): 5515.

https://doi.org/10.1182/blood.V124.21.5515.5515

Published: 2014

Journal Articles

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Soo Young Choi, Sung-Eun Lee, Yun jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, MD, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 1816.

https://doi.org/10.1182/blood.V124.21.1816.1816

Published: 2014

Journal Articles

Evaluation Of Anemia After Long-Term Treatment With Imatinib In Chronic Myeloid Leukemia In Chronic Phase

Muriel Silva Moura, Katia B. Pagnano, MD, PhD, Thais Benevides, Carmino A De Souza, Sr., MD, PhD, Irene Lorand-Metze, MD, PhD, Marcia T Delamain, MD, Gislaine O. Duarte, PhD, Fernando V Pericole, MD, Priscila Percout, Maria Dias, Bruno Duarte, Paula Campos, Paola Assunção, Luciene Oliveira, Pamela Paul, Eliana Fernandes

Blood (2013) 122 (21): 5200.

https://doi.org/10.1182/blood.V122.21.5200.5200

Published: 2013

Journal Articles

A T315I Gate Keeper Mutation Responding To Pegylated Interferon Alfa-2a (Peg-IFN) Monotherapy With Major Molecular Response (MMR4) At 12 Months In An Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patient

Hyacinthe Johnson-Ansah, MD, Dina Naguib, MD, Hervé Mittre, MD, Seyefeddine Kadi, MD, Xavier Troussard, MD

Blood (2013) 122 (21): 5179.

https://doi.org/10.1182/blood.V122.21.5179.5179

Published: 2013

Journal Articles

Impact Of Dedicated CML Clinic On The Outcome Of Patients With Newly Diagnosed CML: Experience Of a Single Canadian Center

Moussab Damlaj, BSc MD, Yury Monczak, PhD, Sarit Assouline, MD

Blood (2013) 122 (21): 5186.

https://doi.org/10.1182/blood.V122.21.5186.5186

Published: 2013

Journal Articles

Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study

David Gomez-Almaguer, MD, Roxana Saldaña-Vázquez, MD, Olga Graciela Cantú-Rodríguez, MD, Cesar H Gutiérrez-Aguirre, MD, Jose Carlos Jaime-Pérez, MD, Luz C. Tarin-Arzaga, MD

Blood (2013) 122 (21): 4034.

https://doi.org/10.1182/blood.V122.21.4034.4034

Published: 2013

Journal Articles

Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party

Blood (2013) 122 (21): 258.

https://doi.org/10.1182/blood.V122.21.258.258

Published: 2013

Journal Articles

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Soo-Young Choi, Sung-Eun Lee, M.D., Yun Jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD, PhD, Sang Kyun Sohn, MD, PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD, PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 1499.

https://doi.org/10.1182/blood.V122.21.1499.1499

Published: 2013

Journal Articles

Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib.

Concetta Quintarelli, PhD, Biagio De Angelis, PhD, Santa Errichiello, PhD, Simona Caruso, Nicola Esposito, PhD, Luigia Luciano, MD, Simona Paratore, PhD, Claudia Galimberti, PhD, Simona Soverini, PhD, Carolina Terragna, PhD, Daniela Cilloni, MD, Giuseppe Saglio, MD, Giovanni Martinelli, Frank Giles, MD, Andreas Hochhaus, MD, Fabrizio Pane

Blood (2012) 120 (21): 2795.

https://doi.org/10.1182/blood.V120.21.2795.2795

Published: 2012

Journal Articles

Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.

Sairah Ahmed, MD, Rima M Saliba, Ph.D, Marcos De Lima, MD, Gabriela Rondon, MD, Partow Kebriaei, MD, Tobi DeAnn Fisher, MPAS, Elias Jabbour, MD, Julianne Chen, Hagop Kantarjian, MD, Paolo Anderlini, MD, Amin M Alousi, MD, Chitra M Hosing, MD, Borje Andersson, MD, PhD, Roy B. Jones, MD, Ph.D., Muzaffar H. Qazilbash, MD, Elizabeth J. Shpall, MD, Sergio Giralt, MD, Richard E Champlin, MD

Blood (2012) 120 (21): 3129.

https://doi.org/10.1182/blood.V120.21.3129.3129

Published: 2012

Journal Articles

Estimating Long-Term Life Expectancy in Philadelphia Chromosome Positive (Ph+) Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results of A Microsimulation Model

Sonya J Snedecor, PhD, Xiang Ji, MS, Matthew Magestro, Andrew M Stein, PhD, Marc Botteman, MSc, MA

Blood (2012) 120 (21): 4441.

https://doi.org/10.1182/blood.V120.21.4441.4441

Published: 2012

Journal Articles

Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate

Marc Botteman, MSc, MA, Matthew Magestro, Alaa Fadhil Alwan, MD, Paul W Manley, PhD, Oleg Zernovak, MD, Richard C. Woodman

Blood (2012) 120 (21): 4439.

https://doi.org/10.1182/blood.V120.21.4439.4439

Published: 2012

Journal Articles

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Blood (2012) 120 (21): 3775.

https://doi.org/10.1182/blood.V120.21.3775.3775

Published: 2012

Journal Articles

Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307

Blood (2012) 120 (21): 3784.

https://doi.org/10.1182/blood.V120.21.3784.3784

Published: 2012

Journal Articles

Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial)

Blood (2011) 118 (21): 2756.

https://doi.org/10.1182/blood.V118.21.2756.2756

Published: 2011

Journal Articles

Evaluation of MMR Concordance Based on Either International Scale (IS) or National Comprehensive Cancer Network (NCCN) Criteria Using Reconstructed “Virtual” CML Patient Profiles From the REVEAL BCR-ABL Methods Comparison Study,

Poluru L. Reddy, PhD, DABCC, Paul Choppa, Mike M. Moradian, PhD, Nicholas T. Potter, PhD, FACMG, Michael M. Quigley, MD, Christopher D. Watt, MD, PhD, Holger Höfling, PhD, Brian Manning, PharmD, Andre Mignault, MS, Brian Mullaney, MD, PhD, Diego Ossa, MD, MSc, Andrew Stein, PhD, Sha-Sha Wang, PhD, Feng Yang, PhD, Meir Wetzler, MD

Blood (2011) 118 (21): 3542.

https://doi.org/10.1182/blood.V118.21.3542.3542

Published: 2011

Journal Articles

Imatinib (IM) Treatment In Chronic Myeloid Leukemia (CML). Clinical Practice Limitations

Alicia Inés Enrico, MD, Georgina Bendek, MD, Maria Virginia Prates, MD, Virginia Guerrero, MD, Juan Jose Napal, MD, Carlos Riscala, MD, Ileana Lopez, MD, Santiago Milone, Jorge Milone, MD

Blood (2011) 118 (21): 4454.

https://doi.org/10.1182/blood.V118.21.4454.4454

Published: 2011

NARROW

Experience of Generic Imatinib As a First Line Therapy for Patients with Chronic Myeloid Leukemia in a Single Reference Institution

Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Impact of Proteomic Profile of Peripheral Blood and Bone Marrow Sera on Molecular Response in Patients with Chronic Myeloid Leukemia: Preliminary Data

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Evaluation Of Anemia After Long-Term Treatment With Imatinib In Chronic Myeloid Leukemia In Chronic Phase

A T315I Gate Keeper Mutation Responding To Pegylated Interferon Alfa-2a (Peg-IFN) Monotherapy With Major Molecular Response (MMR4) At 12 Months In An Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patient

Impact Of Dedicated CML Clinic On The Outcome Of Patients With Newly Diagnosed CML: Experience Of a Single Canadian Center

Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study

Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib.

Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.

Estimating Long-Term Life Expectancy in Philadelphia Chromosome Positive (Ph+) Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results of A Microsimulation Model

Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307

Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial)

Evaluation of MMR Concordance Based on Either International Scale (IS) or National Comprehensive Cancer Network (NCCN) Criteria Using Reconstructed “Virtual” CML Patient Profiles From the REVEAL BCR-ABL Methods Comparison Study,

Imatinib (IM) Treatment In Chronic Myeloid Leukemia (CML). Clinical Practice Limitations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only